Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFEND: Antivirals for Post-Acute COVID-19 Cardiovascular Outcomes
NCT06792214Phase 4Recruiting
- Sponsor
- Mount Sinai Hospital
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of Nirmatrelvir, remdesivir in coronavirus disease 2019 (COVID-19), sponsored by Mount Sinai Hospital. Started Jan 2025; status: recruiting.
02
Drugs
Nirmatrelvirremdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06792214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792214.